Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | METAP2 | P50579 | 1/20 | 0.31 |
| ▸ | METAP1 | P53582 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13435080 | 0.85 | PTGER4 (0.34) | POLBABCB1 | |
| SCHEMBL13435093 | 0.79 | ADRB2 (0.33) | POLB | |
| SCHEMBL13435101 | 0.78 | EPHX1 (0.32) | POLBEPHX1 | |
| SCHEMBL13500175 | 0.78 | LMNA (0.40) | MMP8EPHX1LMNA | |
| SCHEMBL13435111 | 0.78 | SLC1A3 (0.42) | — | |
| SCHEMBL13499732 | 0.76 | MEN1 (0.34) | MMP8EPHX1LMNA | |
| SCHEMBL16342323 | 0.76 | POLB (0.36) | POLB | |
| SCHEMBL13461504 | 0.76 | TSHR (0.34) | MMP8EPHX1LMNA | |
| SCHEMBL13435119 | 0.75 | SLC1A3 (0.45) | METAP2 | |
| SCHEMBL13435094 | 0.72 | MMP8 (0.31) | MMP8EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100069373-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF A BETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100056501-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100048541-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2010-02-25 | — | — | US | disclosed |
| US-20100048541-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2010-02-25 | — | — | US | disclosed |
| US-20090170831-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2009-07-02 | — | — | US | disclosed |
| US-20090170831-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2009-07-02 | — | — | US | disclosed |
| US-7498324-B2 | Substituted lactams as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2009-03-03 | — | — | US | disclosed |
| US-20080221087-A1 | Substituted lactams as inhibitors of abeta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-09-11 | — | — | US | disclosed |
| US-7390802-B2 | Substituted lactams as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA CORPORATION (US) | 2008-06-24 | — | — | US | disclosed |
| US-7276495-B2 | Substituted lactams as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-10-02 | — | — | US | disclosed |
| US-7276495-B2 | Substituted lactams as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-10-02 | — | — | US | disclosed |
| US-20070173491-A1 | Substituted lactams as inhibitors of Abeta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221087-A1 | Substituted lactams as inhibitors of abeta protein production | BACE1, APP, APH1A | POLB 1993/4885MMP8 3228/4885EPHX1 2995/4885 |
| US-20100048541-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BACE1, APP, APH1A | POLB 1993/4885MMP8 3228/4885EPHX1 2995/4885 |
| US-20090170831-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BACE1, APP, APH1A | POLB 1849/4885MMP8 3316/4885EPHX1 3165/4885 |
| US-20070173491-A1 | Substituted lactams as inhibitors of Abeta protein production | BACE1, APP, APH1A | POLB 1993/4885MMP8 3228/4885EPHX1 2995/4885 |
| US-20100069373-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF A BETA PROTEIN PRODUCTION | BACE1, APP, BACE2 | POLB 1750/4885MMP8 3122/4885EPHX1 3161/4885 |
| US-20100056501-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BACE1, APP, APH1A | POLB 1993/4885MMP8 3228/4885EPHX1 2995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.